Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)

Inclusion Criteria: Inclusion Criteria for PD: * Male or female patients aged between 45-75 years old. * Clinical diagnosis of PD according to UK Brain Bank Criteria. * 3 months of clinical stability before study enrolment. * Anti-parkinsonian medication is fixed for at least 3 months prior to study entry. Inclusion Criteria for MS: * Male or female patients 18 years old or older. * Diagnosis of RR-MS according to McDonald criteria. * Expanded Disability Status Scale(EDSS) lower or equal to 5.5. * Stable disease for at least 30 days prior to study entry. * Stable disease-modifying therapy for at least 3 months prior to study entry. Common inclusion criteria for MS and PD: * No changes in drug treatment during 6 months-study treatment. * Patients understand and comply with the study procedure and are able to complete tests and examinations required by the project. * Written informed consent. Inclusion criteria for pediatric patients: * Eligible patients are those clinically stable; * Age range from 1 to 10, between 5 and 30 kg. * Patients not involved in other clinical trials. Exclusion Criteria: Exclusion criteria for PD and MS: * Absolute contraindications to Magnetic Resonance Imaging (MRI). * Concomitant neurological disease or severe co-morbidities able to influence outcomes such as spinal injury, cancer, dementia, or other central nervous system diseases such as stroke, epilepsy or psychiatric disorders; * Total score of Mini-Mental State Examination (MMSE)\<24. * Participating in other clinical trials. * Pregnant/lactating.